KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.

James Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee, Yun Fan, Filippo de Marinis, Eiji Iwama, Takako Inoue, Jerónimo Rodríguez-Cid, Li Zhang, Cheng-Ta Yang, Emmanuel de la Mora Jimenez, Jianying Zhou, Maurice Pérol, Ki Hyeong Lee, David Vicente, Eiki Ichihara, Gregory J Riely, Yiwen Luo, Diana Chirovsky, M Catherine Pietanza, Niyati Bhagwati, Shun Lu

J Clin Oncol 42(34) 4029-4039

PMID39173098
PMCIDPMC11608596
DOI10.1200/JCO.23.02747
发表日期2024-08-22
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

PURPOSE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR-mutant, metastatic non-small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum-based chemotherapy with or without pembrolizumab for TKI-resistant, EGFR-mutant, metastatic nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837). METHODS: Adults with pathologically confirmed stage IV nonsquamous NSCLC, documented DEL19 or L858R EGFR mutation, and progression after EGFR-TKI treatment were randomly assigned 1:1 to 35 cycles of pembrolizumab 200 mg or placebo once every 3 weeks plus four cycles of pemetrexed and carboplatin or cisplatin once every 3 weeks and then maintenance pemetrexed. Dual primary end points were progression-free survival (PFS) and overall survival (OS). Final PFS testing was completed at the second interim analysis (IA2; data cutoff, December 3, 2021); OS was tested at final analysis (FA; data cutoff, January 17, 2023). Efficacy boundaries were one-sided P = .0117 for PFS and OS. RESULTS: Four hundred ninety-two patients were randomly assigned to pembrolizumab plus chemotherapy (n = 245) or placebo plus chemotherapy (n = 247). At IA2, the median PFS was 5.6 months for pembrolizumab plus chemotherapy versus 5.5 months for placebo plus chemotherapy (hazard ratio [HR], 0.80 [95% CI, 0.65 to 0.97]; P = .0122). At FA, the median OS was 15.9 versus 14.7 months, respectively (HR, 0.84 [95% CI, 0.69 to 1.02]; P = .0362). Grade ≥3 treatment-related adverse events occurred in 43.7% of pembrolizumab plus chemotherapy recipients versus 38.6% of placebo plus chemotherapy recipients. CONCLUSION: Addition of pembrolizumab to chemotherapy in patients with TKI-resistant, EGFR-mutant, metastatic nonsquamous NSCLC did not significantly prolong PFS or OS versus placebo plus chemotherapy in KEYNOTE-789.

KM 提取结果

4 个 Figure · 11 个 KM 面板

进入结果中心
KM Figure2 个面板

FIG 2.

FIG 2. PFS and OS. (A) Kaplan-Meier estimates of PFS tested at IA2 according to RECIST version 1.1 by blinded independent central review. (B) Analysis of PFS in key subgroups. (C) Kaplan-Meier estimates of OS tested at protocol-specified final analysis. (D) Analysis of OS in key subgroups. a For the overall population, analysis was based on the Cox regression model with treatment as a covariate stratified by PD-L1 TPS (≥50% or <50%), treatment history (osimertinib or no osimertinib), and geographic region (East Asia or not East Asia). For subgroups, analysis was based on the unstratified Cox regression model with treatment as a covariate. ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR , epidermal growth factor receptor; HR, hazard ratio; IA2, second interim analysis; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor; TPS, tumor proportion score.

A

PFS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 2:extreme upward reversal
查看结果
C

OS

FIG 2. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure4 个面板

FIG 3.

FIG 3. Kaplan-Meier analysis of PFS at IA2 and OS at protocol-specified FA by PD-L1 TPS. (A) PFS in patients with PD-L1 TPS ≥1%. (B) PFS in patients with PD-L1 TPS < 1%. (C) OS in patients with PD-L1 TPS ≥1%. (D) OS in patients with PD-L1 TPS < 1%. FA, final analysis; HR, hazard ratio; IA2, second interim analysis; OS, overall survival; PFS, progression-free survival; TPS, tumor proportion score.

A

PFS

FIG 3. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

FIG 3. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

OS

FIG 3. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

OS

FIG 3. · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

FIG 4.

FIG 4. Kaplan-Meier estimate of time to true deterioration for the composite end point of cough, chest pain, and dyspnea at the protocol-specified final analysis. HR, hazard ratio; NR, not reached.

time_to_deterioration

time to true deterioration for the composite end point of cough, chest pain, and dyspnea

FIG 4. · Panel time_to_deterioration

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel time_to_deterioration 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure4 个面板

FIG A2.

FIG A2. Kaplan-Meier analysis of progression-free survival per RECIST version 1.1 by BICR at IA2 and OS at the final analysis in PD-L1 TPS subgroups. (A) PFS in patients with PD-L1 TPS 1%-49%. (B) PFS in patients with PD-L1 TPS ≥50%. (C) OS in patients with PD-L1 1%-49%. (D) OS in patients with PD-L1 TPS ≥50%. BICR, blinded independent central review; HR, hazard ratio; IA2, second interim analysis; OS, overall survival; PFS, progression-free survival; TPS, tumor proportion score.

A

PFS

FIG A2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

FIG A2. · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
C

OS

FIG A2. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

OS

FIG A2. · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. Patient disposition. ITT, intention to treat.
非 KM Figure
FIG A1.FIG A1. Multiplicity diagram for type I error control. The initial α allocated to each hypothesis is represented in the green boxes with the weights for reallocation from each hypothesis to others represented in the white boxes. If both the PFS and OS hypotheses are rejected, the reallocation strategy allows retesting of ORR at α = .025 on the basis of the P value at IA1. The actual boundaries were updated on the basis of the actual number of events observed and calculated using the Lan-DeMets O'Brien-Fleming spending function with the information fraction on the basis of the minimum of the expected information fraction and the actual information fraction at each analysis. ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
非 KM Figure